Magnetic resonance imaging of a randomized controlled trial investigating predictors of recovery following psychological treatment in adolescents with moderate to severe unipolar depression: study protocol for Magnetic Resonance-Improving Mood with Psychoanalytic and Cognitive Therapies (MR-IMPACT)

BMC Psychiatry

Study Protocol

Raphael Kelvin¹  Barry Widmer²  Rosemary J Holt²  Paul O Wilkinson³  Ian Goodyer³  Adrienne O van Nieuwenhuizen⁴  Julia ME Graham⁴  Cindy C Hagan⁴  Cinly Ooi⁴  Barbara J Sahakian⁵  John Suckling⁶  Edward T Bullmore⁷  Belinda R Lennox⁸  Shirley Reynolds⁹  Peter Fonagy^1,10  Mary Target^1,10 

[1] Brookside Family Consultation Clinic, 18d Trumpington Road, CB2 8AH, Cambridge, UK;Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK;Department of Psychiatry, University of Cambridge, Douglas House, 18b Trumpington Road, CB2 8AH, Cambridge, UK;Department of Psychiatry, University of Cambridge, Douglas House, 18b Trumpington Road, CB2 8AH, Cambridge, UK;Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK;Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Robinson Way, CB2 0SZ, Cambridge, UK;Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Robinson Way, CB2 0SZ, Cambridge, UK;MRC/Wellcome Trust Behavioural and Clinical Neurosciences Institute, University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Robinson Way, CB2 0SZ, Cambridge, UK;Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Robinson Way, CB2 0SZ, Cambridge, UK;MRC/Wellcome Trust Behavioural and Clinical Neurosciences Institute, University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Robinson Way, CB2 0SZ, Cambridge, UK;Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK;Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Robinson Way, CB2 0SZ, Cambridge, UK;MRC/Wellcome Trust Behavioural and Clinical Neurosciences Institute, University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Robinson Way, CB2 0SZ, Cambridge, UK;Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK;GlaxoSmithKline, Clinical Unit Cambridge, Cambridge, UK;Department of Psychiatry, University of Oxford, Warneford Hospital, OX3 7JX, Oxford, UK;Department of Psychological Sciences, Norwich Medical School, University of East Anglia, NR4 7QH, Norwich, UK;Psychoanalysis Unit, Research Department of Clinical, Educational and Health Psychology, University College London, Gower Street, WC1E 6BT, London, UK;

关键词: Cognitive Behavioral Therapy;    Diffusion Tensor Imaging;    Major Depressive Disorder;    Hurst Exponent;    Distractor Word;   

DOI  :  10.1186/1471-244X-13-247

 received in 2013-09-19, accepted in 2013-10-02,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundMajor depressive disorders (MDD) are a debilitating and pervasive group of mental illnesses afflicting many millions of people resulting in the loss of 110 million working days and more than 2,500 suicides per annum. Adolescent MDD patients attending NHS clinics show high rates of recurrence into adult life. A meta-analysis of recent research shows that psychological treatments are not as efficacious as previously thought. Modest treatment outcomes of approximately 65% of cases responding suggest that aetiological and clinical heterogeneity may hamper the better use of existing therapies and discovery of more effective treatments. Information with respect to optimal treatment choice for individuals is lacking, with no validated biomarkers to aid therapeutic decision-making.Methods/DesignMagnetic resonance-Improving Mood with Psychoanalytic and Cognitive Therapies, the MR-IMPACT study, plans to identify brain regions implicated in the pathophysiology of depressions and examine whether there are specific behavioural or neural markers predicting remission and/or subsequent relapse in a subsample of depressed adolescents recruited to the IMPACT randomised controlled trial (Registration # ISRCTN83033550).DiscussionMR-IMPACT is an investigative biomarker component of the IMPACT pragmatic effectiveness trial. The aim of this investigation is to identify neural markers and regional indicators of the pathophysiology of and treatment response for MDD in adolescents. We anticipate that these data may enable more targeted treatment delivery by identifying those patients who may be optimal candidates for therapeutic response.Trial registrationAdjunctive study to IMPACT trial (Current Controlled Trials: ISRCTN83033550).

【 授权许可】

CC BY   
© Hagan et al.; licensee BioMed Central Ltd. 2013